Amedeo Smart

Free Medical Literature Service

 

Amedeo

Dermatology
  Free Subscription

Articles published in
Int J Cancer
    May 2025
  1. XIE X, Chen L, Kong X, Huo Y, et al
    Comparative efficacy and safety of PD-1 versus PD-L1 inhibitors in breast cancer treatment: A systematic review and meta analysis.
    Int J Cancer. 2025;156:1936-1949.
    >> Share

    April 2025
  2. STAERK MG, Kaderly Rasmussen EL, Hannibal CG, Hertzum-Larsen R, et al
    Histologically verified penile lichen sclerosus-Incidence in Denmark over 26 years and long-term risk of penile and non-penile cancer.
    Int J Cancer. 2025 Apr 18. doi: 10.1002/ijc.35454.
    >> Share

  3. PERRIER F, Ahimbisibwe A, Ghiasvand R, Rueegg CS, et al
    Physical activity and mortality in melanoma patients within the Norwegian Women and Cancer study (NOWAC).
    Int J Cancer. 2025 Apr 3. doi: 10.1002/ijc.35430.
    >> Share

    March 2025
  4. VIRAZELS M, Lusque A, Brayer S, Genais M, et al
    TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFalpha clinical study.
    Int J Cancer. 2025 Mar 18. doi: 10.1002/ijc.35416.
    >> Share

    February 2025
  5. SCHWERD-KLEINE P, Wurth R, Cheytan T, Michel L, et al
    Biopsy-derived organoids in personalised early breast cancer care: Challenges of tumour purity and normal cell overgrowth cap their practical utility.
    Int J Cancer. 2025 Feb 28. doi: 10.1002/ijc.35386.
    >> Share

    January 2025
  6. NALWOGA A, Jackson C, Fiorillo S, Manyeruke F, et al
    Evaluation of plasma alpha-1-antichymotrypsin as a marker for pulmonary Kaposi sarcoma.
    Int J Cancer. 2025 Jan 30. doi: 10.1002/ijc.35351.
    >> Share

  7. ZHOU J, Qiu T, Zhang Z, Lan Y, et al
    Consensus statement for the diagnosis, treatment, and prognosis of kaposiform hemangioendothelioma.
    Int J Cancer. 2025 Jan 20. doi: 10.1002/ijc.35344.
    >> Share

  8. LUND E, Busund LR, Holden L
    Curvilinear incidence models for parity in the entire fertility range for cancers of the breast, ovary, and endometrium: A follow-up of the Norwegian 1960 Census.
    Int J Cancer. 2025 Jan 3. doi: 10.1002/ijc.35312.
    >> Share

    December 2024
  9. RODRIGUEZ MS, Mahmoud YD, Vanzulli S, Giulianelli S, et al
    FGFR2-RUNX2 activation: An unexplored therapeutic pathway in luminal breast cancer related to tumor progression.
    Int J Cancer. 2024 Dec 28. doi: 10.1002/ijc.35302.
    >> Share

  10. KOUVARAKI M, Zerdes I, Sifakis EG, Sarafidis M, et al
    Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer.
    Int J Cancer. 2024 Dec 27. doi: 10.1002/ijc.35319.
    >> Share

  11. THILL M, Zahn MO, Welt A, Nusch A, et al
    Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry.
    Int J Cancer. 2024 Dec 20. doi: 10.1002/ijc.35296.
    >> Share

  12. MOUHANNA P, Stahlberg A, Andersson D, Albu-Kareem A, et al
    Integration of personalised ultrasensitive ctDNA monitoring of patients with metastatic breast cancer to reduce imaging requirements.
    Int J Cancer. 2024 Dec 18. doi: 10.1002/ijc.35292.
    >> Share

  13. CHENG TC, Huang BM, Liao YC, Chang HS, et al
    Fibroblast growth factor receptor four inhibitor FGF401 improves the efficacy of trastuzumab in FGFR4-overexpressing breast cancer cells.
    Int J Cancer. 2024 Dec 16. doi: 10.1002/ijc.35271.
    >> Share

  14. CHEN Y, Salas LA, Marotti JD, Jenkins NP, et al
    Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple-negative breast cancer.
    Int J Cancer. 2024 Dec 5. doi: 10.1002/ijc.35274.
    >> Share

    November 2024
  15. HOANG T, Lee J, Jung SY, Kim J, et al
    Determining risk-adapted starting age and interval for breast cancer screening based on reproductive and hormonal factors.
    Int J Cancer. 2024 Nov 27. doi: 10.1002/ijc.35265.
    >> Share

  16. JIANG C, Freedman RA, Punglia RS, Jemal A, et al
    Associations of radiotherapy receipt with lung cancer risk by histological subtype among breast cancer survivors in the United States.
    Int J Cancer. 2024 Nov 13. doi: 10.1002/ijc.35257.
    >> Share

  17. LI T, Zhang M, Zhang T, Li S, et al
    Cyclin-dependent kinase 4/6 inhibitors and cardiotoxic events in breast cancer: A pharmacovigilance study based on the FAERS database.
    Int J Cancer. 2024 Nov 13. doi: 10.1002/ijc.35255.
    >> Share

  18. CAO L, Ou D, Qi WX, Xu C, et al
    A randomized trial of early cardiotoxicity in breast cancer patients receiving postoperative IMRT with or without serial cardiac dose constraints.
    Int J Cancer. 2024 Nov 5. doi: 10.1002/ijc.35245.
    >> Share

  19. SCHEI-ANDERSEN AJ, Hendricks LAJ, van der Post RS, Mensenkamp AR, et al
    Histopathological phenotyping of cancers in PTEN Hamartoma Tumor Syndrome for improved recognition: A single-center study.
    Int J Cancer. 2024;155:1567-1576.
    >> Share

    October 2024
  20. HOLDER EX, Bigham Z, Nelson KP, Barnard ME, et al
    Mammographic density and breast cancer risk among Black American women.
    Int J Cancer. 2024 Oct 19. doi: 10.1002/ijc.35223.
    >> Share

  21. ARIBAL E, Seker ME, Guldogan N, Yilmaz E, et al
    Value of automated breast ultrasound in screening: Standalone and as a supplemental to digital breast tomosynthesis.
    Int J Cancer. 2024;155:1466-1475.
    >> Share

  22. ZHENG Y, Vdovichenko N, Schurmann P, Ramachandran D, et al
    Comparative sequencing study of mismatch repair and homology-directed repair genes in endometrial cancer and breast cancer patients from Kazakhstan.
    Int J Cancer. 2024 Oct 14. doi: 10.1002/ijc.35215.
    >> Share

  23. HAMAD W, Michell MJ, Myles JP, Gilbert FJ, et al
    Diagnostic performance of tomosynthesis plus synthetic mammography versus full-field digital mammography with or without tomosynthesis in breast cancer screening: A systematic review and meta-analysis.
    Int J Cancer. 2024 Oct 12. doi: 10.1002/ijc.35217.
    >> Share

  24. QIU T, Xiang S, Zhou J, Yang M, et al
    Sirolimus for kaposiform hemangioendothelioma: Potential mechanisms of action and resistance.
    Int J Cancer. 2024 Oct 6. doi: 10.1002/ijc.35207.
    >> Share

    September 2024
  25. KE C, Chen M, Lin L, Huang Y, et al
    Postmarketing adverse events of tamoxifen in male and female patients with breast cancer.
    Int J Cancer. 2024 Sep 21. doi: 10.1002/ijc.35193.
    >> Share

  26. PFOB A, Surovtsova I, Kokh DB, Heil J, et al
    Use of chemotherapy and loco-regional therapy in stage IA triple-negative breast cancer and their association with oncologic outcomes: A cancer registry study.
    Int J Cancer. 2024 Sep 18. doi: 10.1002/ijc.35189.
    >> Share

  27. BARNES I, Garcia-Closas M, Gathani T, Sweetland S, et al
    A comparative analysis of risk factor associations with interval and screen-detected breast cancers: A large UK prospective study.
    Int J Cancer. 2024;155:979-987.
    >> Share

  28. KOON SUN PAT M, Manraj M, Manraj S
    Breast cancer survival analysis in the Republic of Mauritius by age, stage at diagnosis and molecular subtype: A retrospective cohort study.
    Int J Cancer. 2024 Sep 7. doi: 10.1002/ijc.35172.
    >> Share

  29. POISEUIL M, Molinie F, Dabakuyo-Yonli TS, Laville I, et al
    Impact of organized and opportunistic screening on excess mortality and on social inequalities in breast cancer survival.
    Int J Cancer. 2024 Sep 7. doi: 10.1002/ijc.35173.
    >> Share

    August 2024
  30. PERERA MM, Smit AK, Smith AL, Gallo B, et al
    Adherence to melanoma screening and surveillance skin check schedules tailored to personal risk.
    Int J Cancer. 2024 Aug 23. doi: 10.1002/ijc.35146.
    >> Share

  31. LIU B, Song Y, Xu Y, Sun Q, et al
    Optimizing treatment sequence for inoperable locally advanced breast cancer: Long-term outcomes of surgery first versus neoadjuvant chemotherapy in a real-world setting.
    Int J Cancer. 2024 Aug 23. doi: 10.1002/ijc.35140.
    >> Share

  32. KIM CE, Pereira A, Binder AM, Amarasiriwardena C, et al
    Time-specific impact of trace metals on breast density of adolescent girls in Santiago, Chile.
    Int J Cancer. 2024;155:627-636.
    >> Share

  33. KINDT CK, Alves CL, Ehmsen S, Kragh A, et al
    Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancer.
    Int J Cancer. 2024 Aug 11. doi: 10.1002/ijc.35126.
    >> Share

    July 2024
  34. LEREVEREND C, Kotaich N, Cartier L, De Boni M, et al
    Enhanced expression of galectin-9 in triple negative breast cancer cells following radiotherapy: Implications for targeted therapy.
    Int J Cancer. 2024 Jul 30. doi: 10.1002/ijc.35107.
    >> Share

  35. FORSCHNER A, Nanz L, Maczey-Leber Y, Amaral T, et al
    Response and outcome of patients with melanoma skin metastases and immune checkpoint inhibition.
    Int J Cancer. 2024 Jul 20. doi: 10.1002/ijc.35103.
    >> Share

  36. KADERLY RASMUSSEN EL, Hannibal CG, Hertzum-Larsen R, Kjaer SK, et al
    Biopsy-verified vulvar lichen sclerosus and the risk of non-vulvar cancer: A nationwide cohort study.
    Int J Cancer. 2024 Jul 17. doi: 10.1002/ijc.35101.
    >> Share

  37. GABRIELSON M, Hammarstrom M, Bergqvist J, Lang K, et al
    Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change.
    Int J Cancer. 2024;155:339-351.
    >> Share

  38. TURNER JA, Van Gulick RJ, Robinson WA, Mughal T, et al
    Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling.
    Int J Cancer. 2024 Jul 12. doi: 10.1002/ijc.35087.
    >> Share

  39. JIANG C, Giaquinto AN, Jemal A, Sung H, et al
    Trends in breast cancer incidence by estrogen receptor status in the United States, 2004-2020.
    Int J Cancer. 2024 Jul 10. doi: 10.1002/ijc.35073.
    >> Share

  40. WOHLFEIL SA, Kranzmann L, Weiss C, von Wasielewski I, et al
    Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg.
    Int J Cancer. 2024 Jul 8. doi: 10.1002/ijc.35078.
    >> Share

  41. BHIMANI J, O'Connell K, Persaud S, Blinder V, et al
    Patient characteristics associated with delayed time to adjuvant chemotherapy among women treated for stage I-IIIA breast cancer.
    Int J Cancer. 2024 Jul 6. doi: 10.1002/ijc.35053.
    >> Share

    June 2024
  42. BLOEM M, van Not OJ, Aarts MJB, van den Berkmortel FWPJ, et al
    Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.
    Int J Cancer. 2024 Jun 24. doi: 10.1002/ijc.35060.
    >> Share

  43. FODA BM, Misek SA, Gallo KA, Neubig RR, et al
    Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade.
    Int J Cancer. 2024 Jun 19. doi: 10.1002/ijc.35056.
    >> Share

  44. KAMEI M, Matsuo K, Yoshida Y, Shimada K, et al
    Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL responses through recruitment of CXCL9-expressing conventional type-1 dendritic cells.
    Int J Cancer. 2024;154:2176-2188.
    >> Share

  45. ANDREOU M, Jakalski M, Duzowska K, Filipowicz N, et al
    Prelude to malignancy: A gene expression signature in normal mammary gland from breast cancer patients suggests pre-tumorous alterations and is associated with adverse outcomes.
    Int J Cancer. 2024 Jun 8. doi: 10.1002/ijc.35050.
    >> Share

    May 2024
  46. DE JONGE C, Schipper RJ, Walstra CJEF, Van Riet YE, et al
    Breast conserving surgery with intraoperative electron beam radiation therapy for low-risk breast cancer: Five-year follow-up of 306 patients.
    Int J Cancer. 2024 May 16. doi: 10.1002/ijc.35033.
    >> Share

  47. HAN X, Liu Y, Zhang S, Li L, et al
    Improving the diagnosis of ductal carcinoma in situ with microinvasion without immunohistochemistry: An innovative method with H&E-stained and multiphoton microscopy images.
    Int J Cancer. 2024;154:1802-1813.
    >> Share

  48. HWANG HW, Shin HT, An HY, Byun JW, et al
    Genomic progression for local invasion of cutaneous squamous cell carcinoma from the superficial to the deep portion.
    Int J Cancer. 2024 May 13. doi: 10.1002/ijc.34952.
    >> Share

  49. BAO Y, Sui X, Wang X, Qu N, et al
    Extrachromosomal circular DNA landscape of breast cancer with lymph node metastasis.
    Int J Cancer. 2024 May 1. doi: 10.1002/ijc.34985.
    >> Share

    April 2024
  50. BRANDT C, Vo JB, Gierach GL, Cheng I, et al
    Second primary cancer risks according to race and ethnicity among U.S. breast cancer survivors.
    Int J Cancer. 2024 Apr 29. doi: 10.1002/ijc.34971.
    >> Share

  51. KNUUTILA JS, Riihila P, Nissinen L, Heiskanen L, et al
    Cancer-associated fibroblast activation predicts progression, metastasis, and prognosis of cutaneous squamous cell carcinoma.
    Int J Cancer. 2024 Apr 22. doi: 10.1002/ijc.34957.
    >> Share

  52. BUDUKH A, Dora T, Sancheti S, Singh V, et al
    Outcome of early detection approach in control of breast, cervical, and oral cancer: Experience from a rural cancer center in India.
    Int J Cancer. 2024 Apr 20. doi: 10.1002/ijc.34966.
    >> Share

  53. FROHLICH LM, Villar-Miyar A, Heintze T, Sauer B, et al
    PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma.
    Int J Cancer. 2024 Apr 15. doi: 10.1002/ijc.34947.
    >> Share

  54. LIN YY, Gao HF, Li H, Hu Q, et al
    Clinical efficacy of tumor organoid-guided cancer therapy for locally advanced unresectable or metastatic breast cancer.
    Int J Cancer. 2024 Apr 5. doi: 10.1002/ijc.34945.
    >> Share

  55. WANG Y, Cai W, He P, Cai Q, et al
    Clinical outcomes of coronavirus disease in patients with breast cancer treated with granulocyte colony-stimulating factor following chemotherapy: Triangulation of evidence using population-based cohort and Mendelian randomization analyses.
    Int J Cancer. 2024 Apr 1. doi: 10.1002/ijc.34914.
    >> Share

    March 2024
  56. WU H, Wang W, Zhang Y, Chen Y, et al
    Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
    Int J Cancer. 2024 Mar 27. doi: 10.1002/ijc.34931.
    >> Share

  57. SONGISO M, Nunez O, Cabanes A, Mutale M, et al
    Three-year survival of breast cancer patients attending a one-stop breast care clinic nested within a primary care health facility in sub-Saharan Africa-Zambia.
    Int J Cancer. 2024 Mar 25. doi: 10.1002/ijc.34920.
    >> Share

  58. DAL MASO L, Toffolutti F, De Paoli A, Giudici F, et al
    Cure indicators and prevalence by stage at diagnosis for breast and colorectal cancer patients: A population-based study in Italy.
    Int J Cancer. 2024 Mar 23. doi: 10.1002/ijc.34923.
    >> Share

  59. BAANDRUP L, Hannibal CG, Hertzum-Larsen R, Kjaer SK, et al
    Biopsy-verified vulvar lichen sclerosus: Incidence trends 1997-2022 and increased risk of vulvar squamous precancer and squamous cell carcinoma.
    Int J Cancer. 2024 Mar 22. doi: 10.1002/ijc.34927.
    >> Share

  60. WANG T, Chai B, Chen WY, Holmes MD, et al
    Metformin and other anti-diabetic medication use and breast cancer incidence in the Nurses' Health Studies.
    Int J Cancer. 2024 Mar 22. doi: 10.1002/ijc.34917.
    >> Share

  61. KREGTING LM, Vrancken Peeters NJMC, Clarijs ME, Koppert LB, et al
    Health utility values of breast cancer treatments and the impact of varying quality of life assumptions on cost-effectiveness.
    Int J Cancer. 2024 Mar 13. doi: 10.1002/ijc.34899.
    >> Share

  62. LUFTNER D, Schuetz F, Schneeweiss A, Hartkopf A, et al
    Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34912.
    >> Share

  63. LIU X, Xie X, Sui C, Liu X, et al
    Unraveling the cross-talk between N6-methyladenosine modification and non-coding RNAs in breast cancer: Mechanisms and clinical implications.
    Int J Cancer. 2024 Mar 1. doi: 10.1002/ijc.34900.
    >> Share

    February 2024
  64. TANG T, Yu H, Xu S, Zhong Y, et al
    Causal effects of endometriosis on cancer risk: A Mendelian randomization study.
    Int J Cancer. 2024 Feb 7. doi: 10.1002/ijc.34876.
    >> Share

  65. SVANOE AA, Humlevik ROC, Knutsvik G, Saele AKM, et al
    Age-related phenotypes in breast cancer: A population-based study.
    Int J Cancer. 2024 Feb 6. doi: 10.1002/ijc.34863.
    >> Share

    January 2024
  66. RYBINSKA I, Mangano N, Romero-Cordoba SL, Regondi V, et al
    SAA1-dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness.
    Int J Cancer. 2024 Jan 30. doi: 10.1002/ijc.34859.
    >> Share

  67. SHARMA MP, Shukla S, Misra G
    Recent advances in breast cancer cell line research.
    Int J Cancer. 2024 Jan 17. doi: 10.1002/ijc.34849.
    >> Share

  68. CHEN H, Yang G, Ma J
    Ocular toxicity associated with anti-HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database.
    Int J Cancer. 2024 Jan 12. doi: 10.1002/ijc.34848.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016